Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia

Autor: Kristina V. Orlova, Mikhail Iu. Fedyanin, Konstantin E. Simanenkov, Aleksandr S. Dergunov, Petr R. Goldshmidt, Aleksandra F. Saydullaeva, Darya V. Bogacheva, Marina A. Yavorskaya, Artur Z. Azanov, Alexander A. Fedenko, Larisa V. Bolotina, Tatyana I. Deshkina, Kseniya G. Babina, Ekaterina A. Kuzevanova, Liudmila G. Zhukova, Polina S. Feoktistova, Natalya I. Polshina, Ekaterina V. Peganova, Valentina E. Shikina, Maksim M. Sobolev, Oleg V. Mironov, Vera A. Vaschenko, Mariya M. Ershova, Agniya O. Mezhueva, Svetlana A. Orlova, Denis A. Tantsyrev, Darya K. Taskina, Antonina A. Teterich, Elena V. Karabina, Yuliya V. Kostalanova, Marina V. Bogacheva, Natalia V. Zhukova, Rashida V. Orlova, Maksim V. Zinkevich, Aleksandr I. Kazmin, Mikhail V. Volkonskiy, Liya M. Voronkova, Anastasiya S. Karpova, Mikhail L. Maleyko, Mariya N. Gorshenina, Elena I. Kryuchkova, Fedor V. Moiseenko, Yuliya I. Murzina, Shamil I. Musin, Andrey N. Ogloblin, Mariya S. Perminova, Regina A. Dumbrava, Sergey A. Emelyanov, Svetlana A. Protsenko, Alexander V. Sultanbaev, Anna V. Tarasova, Elena B. Shakhnovich, Marina V. Demchenkova, Yuliya A. Lozovskaya, Khedi S. Musaeva, Elena M. Pavlova, Roman A. Skotnikov, Vera V. Chernova, Angelina S. Chichkanova, Adina M. Akhmatova, Marina A. Zafirova, Andrey A. Mischenko, Elena N. Ovsienko, Viktoriya A. Petrukhnenko, Oksana A. Syusyukaylova, Yana A. Tyugina, Elena A. Shumilkina, Daniil L. Stroyakovskiy, Aleksandr N. Yurchenkov, Pavel L. Baldin, Anastasiya S. Belova, Olga V. Diduk, Elena A. Konovalova, Lyudmila N. Lebedeva, Yaroslav A. Li, Viktoriya V. Mashtapa, Yana A. Mironenkova, Kristina V. Narovenkova, Olga A. Pavlikova, Elvira L. Parsadanova, Irina S. Pimonova, Anna A. Ruzhnikova, Irina D. Sivunova, Ekaterina P. Soloveva, Maksim I. Sosnin, Kh. Toita Temirsultanova, Makhabbat Zh. Tyulegenova, Aleksandra V. Khodkevich, Nadezhda R. Shakurova, Sureya N. Efendieva, Karine L. Avagimyan, Ekaterina Р. Anokhina, Mariya I. Antoshkina, Stanislav M. Borzyanitsa, Samir K. Dzhentemirov, Marina V. Dmitrochenko, Alla V. Zheleznyak, Yuliya V. Komoza, Aleksandr S. Kopanev, Tatyana I. Kornienko, Margarita A. Krasilnikova, Darya A. Lukhmanova, Natalya S. Mazur, Polina M. Markina, Zhargal S. Mitapov, Svetlana N. Osodoeva, Irina A. Prokopenko, Irina M. Radyukova, Madina S. Ramazanova, Alfiya R. Safarova, Mariya A. Safronova, Khalimat M. Khabrieva, Natalya S. Tsygankova, Kseniya V. Chermakova, Tatyana A. Chirkova, Igor V. Samoylenko, Valeria V. Nazarova, Angelina E. Akhmetyanova, Lev V. Demidov

Publikováno v: Современная онкология, Vol 26, Iss 1, Pp 20-34 (2024)

Background. Prior to the introduction of new agents — immune checkpoint inhibitors — for inoperable and/or metastatic melanoma (IMM), chemotherapy outcomes were generally poor. The median (Me) overall survival (OS) in IMM was no more than 6-9 mon

Externí odkaz: https://doaj.org/article/fff40d04a39d498ba7ec6262154c7020

Osimertinib and routine practice: the experience of the drug application in different clinical situations in case of metastatic non-small cell lung cancer with an EGFR mutation. Case report

Autor: Sergey V. Orlov, Pavel L. Baldin, Natalia V. Diuzeva, Anastasia V. Krechetova, Aleksey A. Mordovskiy, Aleksandr N. Moskovchenko, Natalia E. Musaeva, Olga V. Romanchuk

Publikováno v: Современная онкология, Vol 24, Iss 1, Pp 41-49 (2022)

After the introduce of new treatment options is always important to see how the results of the registered studies will be putted into routine clinical practice. Clinical studies help to assess the efficacy and safety of therapy and to conduct the obj

Externí odkaz: https://doaj.org/article/80055bca9fd14f8eb324e6ab559d677d